Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-491 Efficacy in Hypertension and Type 2 Diabetes
NCT01496430Phase 3Terminated
- Sponsor
- Takeda
- Start
- Jan 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of azilsartan medoxomil in hypertension (HTN), type 2 diabetes mellitus (T2DM), sponsored by Takeda. Started Jan 2012; status: terminated.
02
Drugs
azilsartan medoxomil
03
Conditions
hypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01496430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01496430.